Cyberknife Radiosurgery in Hepatocellular carcinoma with Portal vein tumor thrombosis

Correlation of portal vein tumour thrombus response with survival function following cyberknife radiosurgery in hepatocellular carcinoma patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/02/040384

Enrollment

114

Registered

2022-02-17

Start date

Unknown

Completion date

Unknown

Last updated

2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C220- Liver cell carcinoma

Interventions

Intervention1: Cyberknife Radiosurgery: Cyberknife Radiosurgery to Portal vein tumor thrombosis in Hepatocellular carcinoma 45Gy in 5 fractions after accrual Control Intervention1: NOT APPLICABLE: NOT

Eligibility

Inclusion criteria

Inclusion criteria: Patients with radiologically confirmed HCC with portal vein invasion, willing to participate in the study, having good performance statusâ??Eastern Cooperative Oncology Group (ECOG)â??0 to 2 preserved liver function (bilirubin 3 g/dL, international normalized ratio [INR] < 1.5) no (or mild) ascites, not suitable for TACE, and age above 18 years.

Exclusion criteria

Exclusion criteria: Patients not consenting for the study, poor performance status (ECOG 3â??4), extrahepatic visceral metastases, long PVT involvement ( >7 cm in axial length), Child C with decompensated liver function, large HCC ( >10 cm cumulative length of the mass), and previously treated with radiation therapy for liver lesion and patients who underwent transarterial radioembolization (TARE).

Design outcomes

Primary

Measure	Time frame
Response to treatment with recanalization of portal veinTimepoint: 10 weeks	—

Secondary

Measure	Time frame
survival function, toxicity parameters, factors influencing response to treatment, and feasibility of TACE/TARE in responders.Timepoint: 6 months, 1 year, 2 year	—

Countries

India

Contacts

Public ContactYarlagadda Sreenija

Amrita Institute of Medical Sciences

duttadeb07@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026